January 2015, Vol. 2, No. 1

← Back to Issue

The Evolving Role of Immunotherapeutic Applications in Oncology

Sanjiv S. Agarwala, MD

Letter to Our Readers

Dear Colleague,

Welcome to the 2015 series of Immunotherapy in Oncology (ITO)! In recognition of the enormous advances being made in immuno-oncology and the overwhelming reception by our readership to this journal, the publishers of ITO and I are delighted to announce an increased issuance of this timely and essential journal. Within the 6 issues scheduled for 2015, we will explore applications of immunotherapy in oncology from its well-recognized role in melanoma to emerging uses in other solid tumors and hematologic malignancies with the intent of increasing clinicians’ awareness of immunotherapeutic options for their patients. It is our hope this increased awareness will lead both to improved quality of life and ultimately to increased survival for patients with cancer.

It is our goal to offer the following in ITO:

  • Insightful interviews with those on the forefront of the immunology movement in oncology
  • In-depth articles on forthcoming and FDA-approved immunotherapeutic agents
  • Reviews on the role of immunotherapy used in combination with targeted therapies
  • Updates on therapeutic vaccines
  • News from live events focused on immunotherapeutic strategies

Of note, in this issue we explore immunotherapy topics in hematologic malignancies and breast cancer as well as provide an update on therapeutic vaccines. We hope you find this diverse presentation of the role of immunotherapy interesting, insightful, and ultimately helpful to your understanding of the coming options immunotherapy will offer to your patients. We are enthusiastic about the offerings for 2015 and are pleased to have you in our reading community.


Sanjiv S. Agarwala, MD
ITO Editor in Chief

Uncategorized - February 18, 2015

Monoclonal Antibodies Poised to Be Blockbusters

Monoclonal antibodies may be to multiple myeloma what rituximab has been to lymphoma, according to myeloma experts who expressed enthusiasm over these emerging agents at ASH 2014. “Monoclonal antibodies present an attractive therapeutic strategy,” said Paul G. Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA. “Monoclonal antibodies have activity [ Read More ]

Uncategorized - February 18, 2015

Immune Checkpoint Blockades: The Future of Cancer Therapy

Using the body’s own defenses to kill cancer may sound like the realm of science fiction. However, in the keynote lecture presented at the 2015 Gastrointestinal Cancers Symposium, T cells and antibodies were shown adept at recognizing and targeting antigens created by tumor mutations as they evolve within patients. “The [ Read More ]